[go: up one dir, main page]

CL2012003039A1 - Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. - Google Patents

Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.

Info

Publication number
CL2012003039A1
CL2012003039A1 CL2012003039A CL2012003039A CL2012003039A1 CL 2012003039 A1 CL2012003039 A1 CL 2012003039A1 CL 2012003039 A CL2012003039 A CL 2012003039A CL 2012003039 A CL2012003039 A CL 2012003039A CL 2012003039 A1 CL2012003039 A1 CL 2012003039A1
Authority
CL
Chile
Prior art keywords
polyethylene glycol
conjugated
composition
trauma
disease
Prior art date
Application number
CL2012003039A
Other languages
English (en)
Inventor
William Henry
Original Assignee
Cantab Biopharmaceuticals Patents Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42289987&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2012003039(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cantab Biopharmaceuticals Patents Ltd filed Critical Cantab Biopharmaceuticals Patents Ltd
Publication of CL2012003039A1 publication Critical patent/CL2012003039A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36Blood coagulation or fibrinolysis factors
    • A61K38/37Factors VIII
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CL2012003039A 2010-04-30 2012-10-29 Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre. CL2012003039A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1007357.5A GB201007357D0 (en) 2010-04-30 2010-04-30 Conjugated factor VIII

Publications (1)

Publication Number Publication Date
CL2012003039A1 true CL2012003039A1 (es) 2014-01-24

Family

ID=42289987

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2012003039A CL2012003039A1 (es) 2010-04-30 2012-10-29 Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.

Country Status (26)

Country Link
US (1) US20130150302A1 (es)
EP (1) EP2563402A1 (es)
JP (1) JP5870088B2 (es)
KR (1) KR20130055619A (es)
CN (1) CN102939108A (es)
AP (1) AP2012006575A0 (es)
AU (1) AU2011247147B2 (es)
BR (1) BR112012027590A2 (es)
CA (1) CA2797058A1 (es)
CL (1) CL2012003039A1 (es)
CO (1) CO6660443A2 (es)
CR (1) CR20120579A (es)
EA (1) EA201290938A1 (es)
EC (1) ECSP12012314A (es)
GB (2) GB201007357D0 (es)
IL (1) IL222566A (es)
MX (1) MX2012012683A (es)
MY (1) MY160922A (es)
NI (1) NI201200160A (es)
NZ (1) NZ603939A (es)
PE (1) PE20130254A1 (es)
PH (1) PH12012502150A1 (es)
RU (1) RU2012144555A (es)
SG (1) SG184906A1 (es)
WO (1) WO2011135307A1 (es)
ZA (1) ZA201208989B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351112B2 (en) 2012-04-16 2022-06-07 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5876208B2 (ja) 2006-12-15 2016-03-02 バクスター・インターナショナル・インコーポレイテッドBaxter International Incorp0Rated 延長されたinvivo半減期を有する第VIIa因子−(ポリ)シアル酸結合体
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
JP5909755B2 (ja) 2009-07-27 2016-04-27 リポクセン テクノロジーズ リミテッド 非血液凝固タンパク質の糖ポリシアル酸化
EP3093029A1 (en) 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
SG178141A1 (en) 2009-07-27 2012-03-29 Baxter Int Blood coagulation protein conjugates
DK2654794T3 (da) 2010-12-22 2020-06-08 Baxalta GmbH Materialer og fremgangsmåder til konjugering af et vandopløseligt fedtsyrederivat til et protein
GB201417589D0 (en) 2014-10-06 2014-11-19 Cantab Biopharmaceuticals Patents Ltd Pharmaceutical Formulations
GB201518170D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for subcutaneous administration with intravenous administration of therapeutic agent
GB201518171D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for topical administration with therapeutic agent
GB201518172D0 (en) 2015-10-14 2015-11-25 Cantab Biopharmaceuticals Patents Ltd Colloidal particles for use in medicine
KR20190086269A (ko) * 2018-01-12 2019-07-22 재단법인 목암생명과학연구소 체내 지속형 재조합 당단백질 및 이의 제조방법
KR102575788B1 (ko) 2018-05-18 2023-09-08 정저우 젠사이언시스 인코포레이티드 개선된 fviii 융합 단백질 및 이의 용도

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2572733A1 (en) * 2003-02-26 2013-03-27 Nektar Therapeutics Polymer-factor VIII moiety conjugates
GB0316294D0 (en) 2003-07-11 2003-08-13 Polytherics Ltd Conjugated biological molecules and their preparation
LT1824988T (lt) * 2004-11-12 2017-10-25 Bayer Healthcare Llc Nukreipta į užduotą saitą fviii modifikacija
PL1835938T3 (pl) * 2004-12-27 2014-01-31 Baxalta Inc Koniugaty polimer-czynnik von Willebrandta
CA2647314A1 (en) * 2006-03-31 2007-11-08 Baxter International Inc. Pegylated factor viii
DK2209494T3 (en) 2007-10-09 2016-10-03 Polytherics Ltd New conjugated proteins and peptides
KR20110016440A (ko) * 2008-04-24 2011-02-17 셀틱 파르마 피이지 엘티디. 연장된 반감기를 가진 제 ⅰⅹ 인자 접합체
CN102099058B (zh) * 2008-07-21 2014-10-22 宝力泰锐克斯有限公司 用于缀合生物分子的新试剂和方法
GB0912485D0 (en) * 2009-07-17 2009-08-26 Polytherics Ltd Improved conjugation method

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11351112B2 (en) 2012-04-16 2022-06-07 Cantab Biopharmaceuticals Patents Limited Optimised subcutaneous therapeutic agents

Also Published As

Publication number Publication date
GB2492935B8 (en) 2014-10-29
BR112012027590A2 (pt) 2016-08-09
SG184906A1 (en) 2012-11-29
CA2797058A1 (en) 2011-11-03
MY160922A (en) 2017-03-31
GB2492935A (en) 2013-01-16
MX2012012683A (es) 2013-04-03
JP2013525414A (ja) 2013-06-20
HK1173946A1 (en) 2013-05-31
WO2011135307A1 (en) 2011-11-03
IL222566A (en) 2017-12-31
KR20130055619A (ko) 2013-05-28
PH12012502150A1 (en) 2013-02-04
RU2012144555A (ru) 2014-06-10
GB201220667D0 (en) 2013-01-02
PE20130254A1 (es) 2013-03-16
AU2011247147A1 (en) 2013-01-10
EA201290938A1 (ru) 2013-04-30
AP2012006575A0 (en) 2012-12-31
CR20120579A (es) 2013-04-25
GB2492935A8 (en) 2014-10-29
US20130150302A1 (en) 2013-06-13
GB2492935B (en) 2014-04-30
GB201007357D0 (en) 2010-06-16
IL222566A0 (en) 2012-12-31
AU2011247147B2 (en) 2014-09-18
NZ603939A (en) 2013-08-30
CO6660443A2 (es) 2013-04-30
JP5870088B2 (ja) 2016-02-24
CN102939108A (zh) 2013-02-20
EP2563402A1 (en) 2013-03-06
ZA201208989B (en) 2014-02-26
NI201200160A (es) 2013-04-19
ECSP12012314A (es) 2013-05-31

Similar Documents

Publication Publication Date Title
CL2012003039A1 (es) Polietilenglicol conjugado a factor viii mediante un grupo conector; composicion farmaceutica que comprende dicho polietilenglicol conjugado; uso de dicha composicion para tratamiento de una enfermedad o trauma de la coagulacion de la sangre.
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
IL244858A0 (en) Molecular conjugates of fumarate and a fatty acid, pharmaceutical compositions comprising the same and uses thereof
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
EP2301560A4 (en) PHARMACEUTICAL AGENT FOR PROMOTING THE FUNCTIONAL REGENERATION OF DEGRADED TISSUE
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
EP2857420A4 (en) TARGET TISSUE SPECIFIC ANTIGENBINDING MOLECULE
BRPI1009324A2 (pt) compostos e/ou farmaceuticamente aceitáveis dos mesmos, composição farmacêutica e respectivos usos
EP2911735A4 (en) PERIVASCULAR FABRICATION CATHETER WITH SUPPORT STRUCTURES
EP2911593A4 (en) PERKUTANE TISSUE ANCHORING TECHNIQUES
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
BR112013007577A2 (pt) conjugado, composição farmacêutica, molécula de conjugação com amatoxina e método para a síntese de um conjugado
BR112014016165A8 (pt) compostos de benzaldeído substituído e métodos para seu uso no aumento da oxigenação do tecido
BRPI1006040A2 (pt) uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
BRPI1012276A2 (pt) "dispositivo para distribuir medicamento líquido."
CL2014002464A1 (es) Método para mejorar la eficacia de una transfusión de sangre que comprende la administración de una proteína sanguínea pegilada; oligómero de proteína sanguínea pegilada; proteína sanguínea pegilada; y composición que la comprende.
PL2464342T3 (pl) Formulacje farmaceutyczne do zapobiegania niewłaściwemu użyciu leków medycznych
DK2254549T3 (da) Vandige farmaceutiske sammensætninger, indeholdende borat-polyol-komplekser
EP2827866A4 (en) PHARMACEUTICAL COMPOSITIONS WITH BENZYL ALCOHOL
EP2456365A4 (en) BIOLOGICALLY ACTIVE SEAMS FOR REGENERATIVE MEDICINE
BRPI1009392A2 (pt) "formulação farmacêutica, e, uso de uma quantidade farmaceuticamente eficaz de uma formulação farmacêutica."
PE20151603A1 (es) Anticuerpos anti-lamp1 y conjugados anticuerpo farmaco, y usos de estos
BRPI0907228A2 (pt) Compostos de tienopiridazina, suas preparações, composições farmacêuticas e usos
CL2013000237A1 (es) Composicion farmaceutica que comprende un sirna dirigido a vegfa; y metodo para disminuir la expresion de vegfa in vivo.
BRPI0909101A2 (pt) Adesivos medicinais para cirurgia compreendendo compostos bioativos